Duality Biotherapeutics, a company dedicated to the development of antibody- drug conjugate (ADC), passed the listing hearing of the Stock Exchange, with Morgan Stanley, Jefferies and CITIC Securities being its joint sponsors.

Duality Biotherapeutics has self-discovered two core products, namely DB-1303/BNT323 and DB-1311/BNT324, as well as five other clinical-stage ADCs, two bispecific ADCs and multiple other preclinical ADCs, according to the preliminary prospectus information after the hearing.

Related NewsSPDB Int’l Lists Top 20 Stocks in Terms of Net Southbound Capital Inflow in Past Mth (Table)
Currently, 5 of its clinical-stage assets have obtained investigational new drug approvals from both the US Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA).